Passage Bio Restructures Remix Merger to Two-Step Deal, Adds $70M Pre-Funded Warrant Financing
PASG sits 33% above its 52-week low of $3.29 on light trading volume (0.1× avg).
Summary
Passage Bio amended its reverse merger with Remix Therapeutics to a two-step structure and restructured the concurrent financing to include pre-funded warrants, with approximately $70.0 million in subscriptions at $1.3861 per share or $1.3860 per warrant.
Key Events · M&A and Partnerships · PASG
-
Two-Step Merger Structure Adopted
The Amended and Restated Merger Agreement converts the original single-step merger into a two-step transaction: Merger Sub merges into Remix (First Merger), then the surviving corporation merges into new Merger Sub II LLC (Second Merger), intended to qualify as a tax-free reorganization under Section 368(a).
-
Concurrent Financing Restructured with Pre-Funded Warrants
Investors may now purchase pre-funded warrants to buy Remix common stock in lieu of shares, at $1.3861 per share and $1.3860 per pre-funded warrant, for an aggregate subscription amount of approximately $70.0 million (Total Subscription Amount of $69,999,999.28).
-
Economic Terms Unchanged
The amendment does not modify the aggregate equity value ascribed to Remix or Passage Bio, the minimum proceeds required in the Concurrent Financing, the December 24, 2026 outside date, termination rights, or termination fees — all remain as previously disclosed.
-
Registration Rights Extended to Warrant Shares
The Registration Rights Agreement was revised to cover shares of Passage Bio common stock issuable upon exercise of the pre-funded warrants, with the combined company required to file a resale registration statement within 30 days after the Second Merger effective time.
Analysis · PASG · Life Sciences
Passage Bio and Remix Therapeutics amended their merger agreement on September 2, 2026, converting the original single-step merger into a two-step structure and restructuring the concurrent financing to permit pre-funded warrants. The financing terms are now quantified: approximately $70.0 million at $1.3861 per share or $1.3860 per pre-funded warrant. This is a material update to the reverse merger first announced June 24, 2026 — the deal economics are unchanged, but the mechanics and the financing instrument have shifted. For existing Passage Bio shareholders, who will own only about 6% of the combined company per the S-4 filed July 21, the pre-funded warrant structure adds a new layer of potential dilution, though the aggregate subscription amount remains within the previously disclosed $100M PIPE framework.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $4.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.